TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clomiphene Stair-Step Protocol for Ovulation Induction in Women With Polycystic Ovarian Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:Female in the reproductive age who is subfertile with the diagnosis of polycystic ovarian syndrome, serum FSH≤10 mIU/ml with spontaneous menses or positive bleeding response to progestagen withdrawal.~-~Exclusion Criteria:Male factor (moderate to severe) infertility, bilateral tubal blockage diagnosed by hystrosalpingographgy or laparoscopy and patients on metformin or other medication.~-

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 34 Years
- Healthy Volunteers: t

Study Arms:
- Study of Stair-step Clomiphene Protocol (Type: EXPERIMENTAL): 50 mg clomiphene given for 5 days beginning on day 2 of the cycle. Tv USS done at days 11-14. When there is no response (no follicle \>10 mm), 100 mg clomiphene is initiated immediately for 5 days, and U/S is repeated 1 week after the first tvUSS at day 21. If there is no response, another 150 mg clomiphene is initiated immediately for 5 days and U/S is performed 1week after the second U/S (day28). Ovulation for the stair-step cycles was confirmed by folliculometry (follicle tracing) by tvUSS.
- Traditional Protocol. (Type: ACTIVE_COMPARATOR): Clomiphene medication was initiated at day two of the cycle. The starting dose was 50 mg/day for 5 consecutive days. In case of absent response, the patient was treated with 10 mg medroxyprogesterone acetate (MPA) for10 days. Daily doses of clomiphene citrate were increased by 50 mg in the next cycle up to 3 treatment cycle. In each cycle monitoring of follicular growth was done by tvUSS at day 11-14 of each cycle. First ovulation was used as the endpoint and the duration of follow-up was three treatment cycles (up to 150mg). Ovulation was assessed by tvUSS monitoring of follicle growth.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RCT Comparing EVLA Versus Polidocanol Foam in the Treatment of SSV Insufficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* symptomatic varicose veins (CEAP C2s-C6)~* underlying isolated SSV incompetence (SSV reflux time\>0.5sec on duplex ultrasound (DUS))~* reflux involving at least 15 cm of proximal SSV~* minimal SSV diameter of 4 mm at mid-calf (luminal diameter in standing position)~Exclusion Criteria:~* SSV treatment in the preceding 3 months~* post-thrombotic disease~* deep or superficial vein thrombosis of less than 3 months duration~* coexistent ipsilateral GSV insufficiency~* morbid obesity (BMI\>40)~* presence of significant arterial disease (ABPI\<0.5)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ultrasound-guided-foam sclerotherapy (UGFS) (Type: ACTIVE_COMPARATOR): Injection of Polidocanol foam into SSV
- Endovenous Laser Ablation (EVLA) (Type: ACTIVE_COMPARATOR): Ablation of SSV using laser energy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 30 years old~* Type 2 diabetes by American Diabetes Association criteria~* HbA1c: 6.5% ≤ - \< 10.0%~* Systolic blood pressure: 140 ≤ - \< 180 mmHg or Diastolic blood pressure: 85 ≤ - \< 110 mmHg~* Statin (-) or no change in low to moderate intensity statin \[14\] dose in recent 3 months~Exclusion Criteria:~* Contraindication of olmesartan or amlodipine~* History of RAS inhibitors (ACE inhibitors or ARBs) or calcium channel blockers in the previous 3 months~* Pregnant women, women with potential of pregnancy not using adequate contraception method as evaluated by the investigator, lactating women~* Type 1 diabetes or diabetes secondary to chronic pancreatitis or to pancreatectomy~* Confirmed cardiovascular disease (acute coronary syndrome, stroke, or transient ischemic attack) within 3 months of screening~* Chronic hepatitis B or C (except healthy carrier of HBV), liver disease (AST/ALT \> 3-fold the upper limit of normal)~* Chronic kidney disease (serum creatinine \> 2.0 mg/dL)~* Hyperkalemia serum potassium \>5.0 mEq/L~* Any previous cancer within 5 years (except squamous cell cancer, cervical cancer, thyroid cancer with appropriate treatment) except thyroid cancer or carcinoma in situ

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Olmesartan (Type: EXPERIMENTAL): - Olmesartan group: Olmesartan, 20 (40) mg once a day, oral administration
- Amlodipine (Type: ACTIVE_COMPARATOR): - Comparator group: Amlodipine, 5 (10) mg once a day, oral administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* CD or UC, treated with anti-TNF~Exclusion Criteria:~* Missing data

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fed Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fully understood and voluntarily signed the informed consent form~* With high compliance~* BMI 18.6-28.5 kg/m\^2, and with weight ≥ 50 kg for male, or ≥ 45 kg for female~Exclusion Criteria:~* Allergic to any component of study drugs, other leukotriene receptor antagonists, sulfonamides, or non-steroidal anti-inflammatory drugs~* With clinically relevantly abnormal vital sign, examination, or clinically relevant disease~* Had drug abuse within 3 months before screening or positive in drug of abuse test~* With any routine use of drugs~* Received major surgery within 6 months before study drug administration or planned to receive major surgery during study period~* With average number of cigarettes smoked \> 5/day within 3 months before screening or refused to suspend smoking from 24 hours before study drug administration throughout study period~* With average alcohol consumption \> 14 units/week within 6 months before screening or refused to suspend alcohol consumption from 24 hours before study drug administration throughout study period~* With average tea, coffee, or other drink with caffeine consumption \> 8\*250 mL/day, or refused to suspend tea, coffee, other drink with caffeine, or grape fruit juice consumption from 24 hours before study drug administration throughout study period~* Lost or donated blood \> 200 mL within 3 months, or donated platelet \> 24 U within 1 months before study drug administration~* Received any drug within 14 days before study drug administration~* Received any drug of other clinical trial within 3 months before study drug administration~* Received any vaccine within 4 weeks before study drug administration~* Planned for pregnancy within 3 months after informed consent form signed or refused to use adequate contraception (excluding contraceptive drug)~* For female, pregnant, breastfeeding, received oral contraceptives within 30 days, or contraceptive injection or implant within 6 months before study drug administration~* For pregnancy-capable female, had unprotected sexual contact within 14 days before study drug administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- TR (Type: OTHER): Administration order: montelukast sodium oral thin films with water, montelukast sodium chewable tablets with water.
- RT (Type: OTHER): Administration order: montelukast sodium chewable tablets with water, montelukast sodium oral thin films with water.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Participants in the study must:~1. have acute, non-radicular back strain with onset up to 10 days before the first visit~2. have intact, non-damaged skin at the proposed patch application site~3. be untreated or unresponsive to conservative pain treatment regimens and/or opioids~4. have a minimum pain intensity score of four (4) or more on a scale of 1-10 (a rating of zero (0) being no pain and a rating of ten (10) being pain as bad as you can imagine)~5. have a normal neurologic examination~Exclusion Criteria:~Participants may not be in the study if they:~1. have had surgery or other chronic pain condition within 3 months before first treatment~2. have back pain radiating below the knee at time of enrollment~3. have neuropathic pain or have been treated with gabapentin or pregabalin for neuropathy~4. are being treated for or are known to currently have kidney or liver disease~5. have certain other diseases or are using certain types of other drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FLECTORA Patch (diclofenac epolamine topical patch) 1.3% (Type: EXPERIMENTAL): One patch applied every 12 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Male and female between the ages of 30 to 80 years with diagnosis of idiopathic Parkinson's Disease of more than 5 years duration, with a Hoehn and Yahr stage of I-IV during an off phase.~Be levodopa-responsive and have been receiving treatment with a stable dose of levodopa for at least 4 weeks.~Have motor fluctuations, with \>1.5 hours off time during the day. Be able to maintain an accurate and complete diary (18-hour)~Exclusion Criteria:~Patients with medical conditions and/or taking concomitant medications that would have put them at risk, interfered with the study evaluations, or made them unable to complete the requirements of the study;.~Be in a late stage of Parkinson's Disease, and experiencing severe, disabling peak-dose or biphasic dyskinesia and/or unpredictable or widely swinging fluctuations in their symptoms.~Current diagnosis of substance abuse or history of alcohol or drug abuse in the past 3 months.~Have received treatment with safinamide previously. History of, or current depression psychosis (e.g. schizophrenia or psychotic depression) Evidence of dementia or cognitive dysfunction. History of allergic response to anticonvulsants, levodopa, or other anti-Parkinsonian agents.~Hypersensitivity or contraindications to MAO-B inhibitors. Ophthalmologic history including any of the following conditions: albino subjects, family history of hereditary retinal disease, progressive and/or severe diminution of visual acuity (i.e., 20/70), retinitis pigmentosa, retinal pigmentation due to any cause, any active retinopathy or ocular inflammation (uveitis), or diabetic retinopathy.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 1 active (50 - 100 mg/day)
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Prophylaxy of Amiodarone and Propranolol and Amiodarone With Propranolol in Prevention of Atrial Fibrillation Post Coronary Artery Bypass Graft

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient who are going to have elective CABG~* Signing informed consent~Exclusion Criteria:~* EF\<35%~* Bradycardia\<60 per min~* Hypotension\< 100 mmhg

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- P (Type: EXPERIMENTAL): Propranolol from 7 days pre-operation to 5 days post CABG
- A (Type: ACTIVE_COMPARATOR): Amiodarone treated 7 days pre-operation to 5 days post CABG
- AP (Type: ACTIVE_COMPARATOR): Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non- metastasis, unresectable, adenocarcinoma pancreatic cancer patients~* No prior anticancer therapy for pancreatic cancer~  •≥ 18 years of age with a performance status of 0 or 1•Adequate complete blood counts, hepatic function, and renal function~* Signed informed Consent~Exclusion Criteria:~* Active bacterial, viral, or fungal infection~* Infection with hepatitis B or C, or history of human immunodeficiency virus (HIV) infection, or receiving immunosuppressive or myelosuppressive~* Subjects with sensory neuropathy, ascites, or plastic biliary stent.~* Serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders (including but not limited to connective tissue disorders, lung disease, and cardiac or seizure disorders)~* Women who are pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nab-Paclitaxel plus Gemcitabine (Type: EXPERIMENTAL): nab-Paclitaxel 125 mg/m2 intravenous (IV) infusion over approximately 30 to 45 minutes on Days 1, 8, and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle Subjects who complete 6 cycles of nab-paclitaxel and gemcitabine without disease progression or unacceptable toxicities, the Investigator will then determine the best option for the subject.~* Continuation of nab-paclitaxel and gemcitabine therapy to disease progression or unacceptable toxicity OR~* Chemoradiation therapy consisting of the concurrent use of capecitabine or gemcitabine with radiation according to institutional practice OR~* Surgical intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol)~* The decision to initiate treatment with commercially available semaglutide has been made by the patient/Legally Acceptable Representative and the treating physician before and independently from the decision to include the patient in this study~* Male or female, age greater than or equal to 18 years at the time of signing informed consent~* Diagnosed with type 2 diabetes at least 12 weeks prior to inclusion~* Available and documented haemoglobin A1c (HbA1c) value less than or equal to 12 weeks prior to initiation of semaglutide treatment~Exclusion Criteria:~* Previous participation in this study. Participation is defined as having given informed consent in this study~* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation~* Treatment with any investigational drug within 90 days prior to enrolment into the study~* Hypersensitivity to semaglutide or to any of the excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: None): Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Passive Tactile Stimulation for Stroke Rehabilitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 and older.~* diagnosis of stroke with upper extremity spasticity or other movement deficits that affect strength and range of movement.~* willing to participate in the vibrotactile stimulation sessions for consecutive days and willing to return for follow up visits as needed for the PHASE in progress.~* able to provide informed consent.~Exclusion Criteria:~* Patients with severe contracture that precludes Modified Ashworth Score (MAS) testing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acute Stimulation: Vibration pattern 1-3 and sham control (Type: ACTIVE_COMPARATOR): All participants try on several wearable prototypes in our laboratory that provide vibration or sham stimulation to the arm. Sensors or electrodes taped onto the arm and hand will sense muscle activity and record any changes during periods of vibration and periods with vibration turned off.
- Longitudinal Stimulation: Vibration pattern 4 (Type: ACTIVE_COMPARATOR): 1) If the patient gets Botox injections in their hand and arm, their arm function will be measured for three months during this standard care. 2) Next, all patients will be given a wearable device to take home. The patient will wear the device while feeling vibrations for 3 hours during the day while awake for two months. During this time and 1 month after this intervention, arm function will be tested.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Platelet Reactivity (High On-Treatment Platelet Reactivity) as Guidance for APT (Antiplatelet Therapy) Adjustment After PCI (Percutaneous Coronary Intervention)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1 under DAPT (dual antiplatelet therapy) of stable angina patients for elective stent implantation.~2. DAPT 24 hours, 7d and 30d after treatment PRU (platelet activity units) values. (Drug unresponsive patients was defined as PRU\> 235).~Exclusion Criteria:~1.Not suitable for the treatment of patients with DAPT. (Active peptic ulceration or bleeding) 2 patients of aspirin, clopidogrel, ticagrelor, cilostazol medication intolerance.~3 contraindications for aspirin, clopidogrel, ticagrelor, cilostazol drug usage (such as heart failure patients not suitable for use cilostazol).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- clopidogrel (Type: None): treated with cloopidogrel
- ticagrelor (Type: None): treated with ticagrelor
- cilostazol (Type: None): treated with clopidogrel+cilostazol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate-to-severe chronic low back pain present for at least 3 months.~* Require a continuous around-the-clock opioid analgesic for an extended period of time.~* Refrain from taking other opioid and non-opioid medications during the study.~Exclusion Criteria:~* Active or within a past 2 years a history of lumbosacral radiculopathy or chronic low back pain due to other underlying disorders such as spinal stenosis with neurologic impairment, cancer, infection, or post-surgical intervention.~* Documented diagnosis of ongoing pain due to other chronic pain conditions which may interfere with assessment of chronic low back pain.~* Active or ongoing or history of alcohol or drug abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ALO-02 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete